As many other oncologists will also attest, we were taught this was a dead end
It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted
And yet here we are, with truly meaningful survival curves👇
Inspiration on multiple levels
#ASCO26
What I love about this news is that this is not simply a new pancreatic cancer drug. It’s that KRAS, one of cancer biology’s most notorious undruggable targets, has finally become druggable.
A powerful reminder that persistence in science can eventually unlock the impossible.